Apr 24 |
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
|
Apr 22 |
Amarin Announces Results of Annual General Meeting of Shareholders
|
Apr 16 |
Amarin Corporation: Small Signs Of Recovery May Not Be Enough
|
Apr 15 |
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
|
Apr 8 |
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
|
Apr 8 |
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
|
Apr 6 |
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
|
Apr 4 |
Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe
|
Apr 3 |
Why Amarin Stock Was Rocketing Higher on Wednesday
|
Apr 3 |
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
|